Therapeutics Initiative

From Wikipedia, the free encyclopedia
Therapeutics Letter
Logo of the Therapeutics Initiative.jpg
DisciplineMedicine, pharmacology
LanguageEnglish
Publication details
History1994-present
Publisher
Therapeutics initiative (Canada)
FrequencyBimonthly
Standard abbreviations
ISO 4Ther. Lett.
Indexing
ISSN2369-8683 (print)
2369-8691 (web)
Links

The Therapeutics Initiative (TI) is an independent organization at the University of British Columbia (UBC) which looks at the effectiveness of medications and provides education to health care providers in British Columbia about the use of medications.[1][2] It was founded in 1994 by the British Columbia Ministry of Health.[1] In 2013 support for the initiative was taken over by UBC.[3]

When requested it additionally looks at specific medications to generate reports for PharmaCare.[1] These reports are generated without look at costs just medication effects.[1] This is done independently of the pharmaceutical industry and government.[4]

They additionally publish the "Therapeutics Letter"[4] and are part of the International Society of Drug Bulletins.[5]

Controversy[]

In 2008 a pharmaceutical task force created by the British Columbia government published a report on the Therapeutics Initiative.[4] The task force members included Russell Williams who was then head of Canada’s Research-Based Pharmaceutical Companies (Rx&D) and employees of Angiotech Pharmaceuticals.[4] They recommended closing the TI.[4]

See also[]

References[]

  1. ^ a b c d Bassett, Ken (May 2006). "Therapeutics Initiative--role and function". BCMJ. 40 (4): 163.
  2. ^ Kaufert, P; Kaufert, J (15 July 2008). "Distressing news on the Therapeutics Initiative". Canadian Medical Association Journal. 179 (2): 164. doi:10.1503/cmaj.1080074. PMC 2443219. PMID 18625994.
  3. ^ Webster, PC (11 June 2013). "UBC takes over Therapeutics Initiative after provincial cuts". Canadian Medical Association Journal. 185 (9): 758. doi:10.1503/cmaj.109-4485. PMC 3680554. PMID 23649419.
  4. ^ a b c d e Silversides, A (1 July 2008). "Highly lauded drug assessment program under attack". Canadian Medical Association Journal. 179 (1): 26–7. doi:10.1503/cmaj.080845. PMC 2464479. PMID 18509096.
  5. ^ "Therapeutics Letter". Retrieved 25 December 2015.
Retrieved from ""